Clinical Trials Directory

Trials / Recruiting

RecruitingNCT06472999

Nephroprotective Measures in Critically Ill Patients With Moderate/Severe Acute Kidney Injury

Implementation of Nephroprotective Measures in Critically Ill Patients With Moderate/Severe Acute Kidney Injury (AKI) - an Observational Study

Status
Recruiting
Phase
Study type
Observational
Enrollment
257 (estimated)
Sponsor
Universität Münster · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers

Summary

This study investigates to which extent recommended nephroprotective measures are implemented in critically ill patients with moderate or severe acute kidney injury.

Detailed description

Acute kidney injury (AKI) is a global problem affecting more than 10% of all hospitalized patients and up to 50% of critically ill patients, with survival related not only to the severity,1 but also to the duration of renal dysfunction.2 Recent evidence suggests that two-thirds of patients with AKI resolve their renal dysfunction within 3-7 days whereas those in whom renal dysfunctions persist have dramatically reduced survival over the following year.2 Persistence of AKI is of grave importance in that it increases an individual's risk of developing chronic kidney disease (CKD) which is a major cause of morbidity and mortality. This link between AKI and CKD has been established over the last decade3 and specific recommendations for the management of patients with AKI have been proposed in order to potentially influence this transition.4 To date, there are no specific pharmacological options for preventing or treating AKI, which is why new approaches and intensive efforts are urgently needed to reduce the occurrence of AKI. The Kidney Disease: Improving Global Outcomes (KDIGO) clinical practice guidelines recommend implementing a bundle of different supportive measures, which, in theory, should be initiated in all patients with AKI in order to prevent disease progression. However, clinical practice and recent studies have shown that the implementation of the KDIGO bundle is still not standard clinical practice despite the fact that evidence suggest clear effectiveness in the reduction of AKI rates.5-9 Poor implementation of nephroprotective measures presents a major missed opportunity to reduce AKI-related morbidity and mortality and to improve long-term outcomes. To investigate the extent to which nephroprotective measures are implemented in patients with AKI can reduce the occurrence of persistent surgical AKI, a multi-center prospective cohort study will be performed.

Conditions

Interventions

TypeNameDescription
PROCEDURENephroprotective measuresDue to the observational design of the study, no study specific interventions are performed. The treatment of the patients is completely guided by the responsible physicians.

Timeline

Start date
2024-07-24
Primary completion
2025-03-01
Completion
2025-09-01
First posted
2024-06-25
Last updated
2024-12-12

Locations

3 sites across 3 countries: Austria, Germany, Netherlands

Source: ClinicalTrials.gov record NCT06472999. Inclusion in this directory is not an endorsement.